GSK markets over 25 vaccines worldwide to prevent potentially life-threatening or crippling illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis.
The majority of our vaccine R&D activities are conducted at GlaxoSmithKline Biologicals in Rixensart, Belgium. Over 1,300 of our research scientists are devoted to developing new vaccines and more cost-effective and convenient combination vaccines to prevent infections that cause serious medical problems worldwide.
We are also targeting therapeutic vaccines that may prevent relapse in cancer patients. The strength of our vaccine pipeline will provide opportunities for us to consistently deliver new vaccines for many years to come.
GSK provides access to basic information on our products as approved by Health Canada to health-care professionals and patients. Federal regulations restrict the level of detail pharmaceutical companies are able to provide via the Internet and other media. If you require more detailed information, please contact your physician, pharmacist or other qualified healthcare professional. The information in this section is only intended for residents of Canada.
Within this section of our website, you find Product Information for our vaccines. Please note that this information is specific to Canada and is not intended to replace the advice of a qualified doctor.
GlaxoSmithKline is the leading Canadian influenza vaccine manufacturer and will supply the majority of the Canadian government’s seasonal influenza vaccines purchases from 2005-2011.
GlaxoSmithKline maintains two state-of-the-art manufacturing facilities dedicated to the production of innovative vaccines in Quebec City and Laval, Quebec.